Research Summary

I am a physician-scientist focused on clinical and translational research aimed at improving outcomes for patients with prostate cancer. My research interests include 1) the discovery of prognostic/predictive biomarkers in prostate cancer and 2) the development of rational approaches of targeted treatment for therapy-resistant disease. My laboratory focuses on sequencing and microarray-based approaches to identify molecular determinants of response from samples from prostate cancer patients treated on clinical trials. In addition, I am co-principal investigator of one of the first biomarker-driven clinical trials for patients with metastatic prostate cancer (NCI 9012; NCT01576172) and oversee a clinic focused on prostate cancer patients.

Research Funding

  • July 1, 2020 - June 30, 2025 - Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA240582
  • July 1, 2019 - June 30, 2024 - MELT: Modulation of PSMA Expression for Lutetium Therapy, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA235741
  • December 14, 2018 - November 30, 2023 - Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA227025
  • September 1, 2018 - August 31, 2023 - DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA230516

Education

Stanford University, B.S., 06/1998, Biological Studies
Washington University School of Medicine, M.D., 06/2002, Medicine

Honors & Awards

  • 1997
    Barry M. Goldwater Fellowship for Excellence in Mathematics, Science, and Engineering
  • 1998-2002
    Dr. Philip Majerus Distinguished Alumni Scholarship
  • 2002
    Dr. Richard S. Brookings Medical School Prize
  • 2008
    American Society of Therapeutic Radiology and Oncology Resident Clinical Research Award
  • 2010
    Radiological Society of North America Roentgen Resident/Fellow Research Award
  • 2012
    American Society of Radiation Oncology Basic Science Award
  • 2014
    Radiobiology Teacher of the Year, Dept of Radiation Oncology, University of Michigan
  • 2016
    American Society of Radiation Oncology Clinical Science Award

Selected Publications

  1. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.  View on PubMed
  2. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan A, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.  View on PubMed
  3. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.  View on PubMed
  4. Ahmed M, Soares F, Xia JH, Yang Y, Li J, Guo H, Su P, Tian Y, Lee HJ, Wang M, Akhtar N, Houlahan KE, Bosch A, Zhou S, Mazrooei P, Hua JT, Chen S, Petricca J, Zeng Y, Davies A, Fraser M, Quigley DA, Feng FY, Boutros PC, Lupien M, Zoubeidi A, Wang L, Walsh MJ, Wang T, Ren S, Wei GH, He HH CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.  View on PubMed
  5. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS Differential Treatment Outcomes in BRCA1/2-, CDK12-, and ATM-Mutated Metastatic Castration-Resistant Prostate Cancer.  View on PubMed
  6. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.  View on PubMed
  7. Feng F, Chen AP, Wang XL, Wu GL Circ_0061140 promotes metastasis of bladder cancer through adsorbing microRNA-1236.  View on PubMed
  8. Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, Jaworski EM, McFarlane MR, Mahal BA, Nguyen PL, Sandler H, Morgan TM, Reichert ZR, Alumkal JJ, Mehra R, Kishan AU, Fizazi K, Halabi S, Schaeffer EM, Feng FY, Elliott D, Dess RT, Jackson WC, Schipper MJ, Spratt DE Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.  View on PubMed
  9. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.  View on PubMed
  10. Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.  View on PubMed
  11. Shafi AA, McNair CM, McCann JJ, Alshalalfa M, Shostak A, Severson TM, Zhu Y, Bergman A, Gordon N, Mandigo AC, Chand SN, Gallagher P, Dylgjeri E, Laufer TS, Vasilevskaya IA, Schiewer MJ, Brunner M, Feng FY, Zwart W, Knudsen KE The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.  View on PubMed
  12. Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P, Tran PT The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.  View on PubMed
  13. Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG Preserving Well-being in Patients With Advanced and Late Prostate Cancer.  View on PubMed
  14. Hofmann MR, Hussain M, Dehm SM, Beltran H, Wyatt AW, Halabi S, Sweeney C, Scher HI, Ryan CJ, Feng FY, Attard G, Klein E, Miyahira A, Soule H, Sharifi N Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.  View on PubMed
  15. Garriga M, Feng FY, Lee WR, Hong JC Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy.  View on PubMed
  16. Tranel J, Feng FY, St James ST, Hope TA Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow.  View on PubMed
  17. Wang S, Li J, Hua J, Su Y, Beckford Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J Molecular imaging of prostate cancer targeting CD46 using immunoPET.  View on PubMed
  18. Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.  View on PubMed
  19. Jairath NK, Dal Pra A, Vince R, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer.  View on PubMed
  20. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, Alumkal JJ, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CAF Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.  View on PubMed

Go to UCSF Profiles, powered by CTSI